These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 2605826)

  • 1. [Intellectual impairments in patients with Parkinson's disease--a proposal of the subgroups of the disease].
    Nishimatsu O; Horiguchi J; Inami Y; Sukegawa T; Shoda M
    Rinsho Shinkeigaku; 1989 Oct; 29(10):1216-20. PubMed ID: 2605826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical study on intellectual impairment in parkinsonian patients during long-term treatment.
    Horiguchi J; Nishimatsu O; Inami Y; Sukegawa T; Shoda T
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):13-8. PubMed ID: 1753458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates].
    Kashihara K; Ohno M; Katsu Y
    Rinsho Shinkeigaku; 2005 Jan; 45(1):1-5. PubMed ID: 15714992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Motor evoked potentials of transcranial magnetic stimulation for Parkinson's disease].
    Shimamoto H; Morimitsu H; Sugita S; Kimihiro N; Shigemori M; Kurihara Y
    No To Shinkei; 1996 Sep; 48(9):825-9. PubMed ID: 8888031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli.
    Bowers D; Miller K; Mikos A; Kirsch-Darrow L; Springer U; Fernandez H; Foote K; Okun M
    Brain; 2006 Dec; 129(Pt 12):3356-65. PubMed ID: 17095520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Young onset Parkinson's disease.
    Quinn N; Critchley P; Marsden CD
    Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of age and severity on the risk of dementia in Parkinson's disease.
    Levy G; Schupf N; Tang MX; Cote LJ; Louis ED; Mejia H; Stern Y; Marder K
    Ann Neurol; 2002 Jun; 51(6):722-9. PubMed ID: 12112078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences.
    Schrag A; Hovris A; Morley D; Quinn N; Jahanshahi M
    Mov Disord; 2003 Nov; 18(11):1250-6. PubMed ID: 14639664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A psychometric study of a group of Parkinsonian patients].
    Gil R; Lefevre JP
    Rev Neurol (Paris); 1980; 135(12):903-22. PubMed ID: 7466117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtypes of Parkinson's disease defined by intellectual impairment.
    Mortimer JA; Jun SP; Kuskowski MA; Webster DD
    J Neural Transm Suppl; 1987; 24():101-4. PubMed ID: 3479520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of effectiveness of the micrographia's therapy in Parkinson's disease patients].
    Jarzebska E
    Pol Merkur Lekarski; 2006 Jun; 20(120):688-90. PubMed ID: 17007269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Parkinson's disease, side affected and depression].
    Serrano-Dueñas M
    Rev Neurol; 2000 Dec 16-31; 31(12):1109-12. PubMed ID: 11205540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.
    Schrag A; Ben-Shlomo Y; Brown R; Marsden CD; Quinn N
    Mov Disord; 1998 Nov; 13(6):885-94. PubMed ID: 9827611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment, disability, and life satisfaction in Parkinson's disease.
    Dural A; Atay MB; Akbostanci C; Kucukdeveci A
    Disabil Rehabil; 2003 Apr; 25(7):318-23. PubMed ID: 12745955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of motor impairment influences quality of life in Parkinson's disease.
    Stewart KC; Fernandez HH; Okun MS; Jacobson CE; Hass CJ
    Mov Disord; 2008 Jul; 23(10):1466-8. PubMed ID: 18546324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of early dopa treatment in Parkinson's disease.
    Markham CH; Diamond SG
    Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.